DaVita Venture Group

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease, particularly targeting secondary hyperparathyroidism (SHPT). SHPT is a condition characterized by the overactivity of the parathyroid glands, resulting from diseases outside of these glands, leading to excessive production of parathyroid hormone (PTH). The company's lead product, upacicalcet, is a novel calcimimetic designed to improve treatment outcomes for hemodialysis patients by mimicking calcium's effects on tissues through the activation of calcium-sensing receptors found in various human organs. Pathalys aims to address significant unmet medical needs in the management of SHPT, ultimately enhancing the quality of care for patients with end-stage chronic kidney disease.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Dock Health is a Boston-based company established in 2016 that develops a HIPAA-compliant task management and collaboration platform specifically for the healthcare sector. The company aims to address significant workflow challenges and inefficiencies faced by clinicians and their teams by providing a reliable and secure system for communication and task management. Through its thoughtfully designed platform, Dock Health empowers healthcare professionals across various settings and specialties to enhance collaboration, ultimately improving patient care. By streamlining processes and facilitating effective teamwork, Dock Health is committed to transforming the organizational and operational dynamics of healthcare providers.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease, particularly targeting secondary hyperparathyroidism (SHPT). SHPT is a condition characterized by the overactivity of the parathyroid glands, resulting from diseases outside of these glands, leading to excessive production of parathyroid hormone (PTH). The company's lead product, upacicalcet, is a novel calcimimetic designed to improve treatment outcomes for hemodialysis patients by mimicking calcium's effects on tissues through the activation of calcium-sensing receptors found in various human organs. Pathalys aims to address significant unmet medical needs in the management of SHPT, ultimately enhancing the quality of care for patients with end-stage chronic kidney disease.

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease, particularly targeting secondary hyperparathyroidism (SHPT). SHPT is a condition characterized by the overactivity of the parathyroid glands, resulting from diseases outside of these glands, leading to excessive production of parathyroid hormone (PTH). The company's lead product, upacicalcet, is a novel calcimimetic designed to improve treatment outcomes for hemodialysis patients by mimicking calcium's effects on tissues through the activation of calcium-sensing receptors found in various human organs. Pathalys aims to address significant unmet medical needs in the management of SHPT, ultimately enhancing the quality of care for patients with end-stage chronic kidney disease.

Heartbeat Health, Inc. is a healthcare technology company based in New York that specializes in cardiology services. Founded in 2017, it provides virtual-first solutions for the prevention and management of cardiovascular disease. The company utilizes a data-powered platform to facilitate real-time consultations between patients and physicians, enabling secure communication and collaboration on treatment and dietary advice. By offering tools that allow patients to monitor their heart health, Heartbeat Health aims to reduce cardiovascular risk and the likelihood of adverse health events. Its comprehensive approach enhances patient care and supports at-risk organizations through a focus on higher-value healthcare delivery.

NephroSant is an innovative diagnostic startup established by a team of physicians and experts in science, engineering, and clinical research, dedicated to enhancing global kidney health. The company has developed a urine-based diagnostic tool that enables the quantitative measurement of biomarkers crucial for the early detection and ongoing monitoring of kidney disease. This noninvasive tool is particularly valuable for physicians, as it aids in predicting and preventing the progression of kidney disease and facilitates the early detection of acute rejection in kidney transplant patients. Through their research-driven approach, NephroSant aims to significantly improve patient outcomes in kidney health.

SameSky Health is a developer of a patient engagement platform designed to connect payers, providers, and health systems with multicultural Medicare patient populations. The company offers integrated services through a web and application-based platform that includes multi-channel messaging, care navigation, and data insights. By addressing the specific needs of culturally diverse populations, SameSky Health aims to guide these individuals through the complexities of the healthcare system. The platform enhances client engagement, reduces unnecessary emergency room visits, and improves overall health outcomes and quality of care.

Wellth is a digital health company based in New York that operates a mobile application aimed at improving treatment adherence among individuals with chronic conditions. The platform leverages principles from behavioral economics to address the unique challenges faced by these patients in establishing healthy habits and managing their diseases. By offering targeted incentive plans, reminders, and valuable information, Wellth encourages consumers to take proactive steps toward their health, thus reducing overall healthcare costs. The application's design fosters motivation and behavior change, as it is supported by evidence from randomized controlled trials demonstrating its effectiveness. Wellth's approach has been validated by health plans and providers, resulting in improved medication adherence, reduced hospital readmissions, and better health outcomes for users.